Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • CGEM (NMS)

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

617 410 4650 One Main Street, Cambridge, MA 02142, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance
Yahoo Finance • Dec 17
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGF - PR Newswire
PR Newswire • Nov 20
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5% - What's Next? - MarketBeat
MarketBeat • Dec 15
Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq
Nasdaq • Dec 21
Cullinan Therapeutics: Worthy Of A Small Position - Seeking Alpha
Seeking Alpha • Oct 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Cullinan Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Cullinan Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Cullinan Therapeutics, Inc. have?
Cullinan Therapeutics, Inc. has approximately 111 employees.
What industry is Cullinan Therapeutics, Inc. in?
Cullinan Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Cullinan Therapeutics, Inc. a publicly traded company?
Yes, Cullinan Therapeutics, Inc. is publicly traded under the ticker symbol CGEM on the NMS. The company has a market capitalization of approximately $0.61 billion.
Where is Cullinan Therapeutics, Inc. headquartered?
Cullinan Therapeutics, Inc. is headquartered in Cambridge, MA, United States at One Main Street, Cambridge, MA 02142, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.